633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial. - Fizazi, K.; Shore, N.; Smith, M.R.; Tammela, T.L.; Le Berre, M-A.; Petrenciuc, O.; Zurth, C.; Kuss, I. (Annals of Oncology, 2020)